Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Evaluate the Safety, PK, PD, and Clinical Activity of STC-15, a METTL-3 Inhibitor, in Subjects With Advanced Malignancies

NCT05584111 is registered in ClinicalTrials.gov with STORM Therapeutics LTD as lead sponsor.

NCT NCT05584111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05584111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Evaluate the Safety, PK, PD, and Clinical Activity of STC-15, a METTL-3 Inhibitor, in Subjects With Advanced Malignancies
Lead sponsor
STORM Therapeutics LTD
Phase
Phase 1
Overall status
Completed
Start date
November 15, 2022
Completion date
December 22, 2024
Enrollment
42 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, cancer